RE: (HEMO)22 May 2021 14:09
Nice find and very interesting!
Dr Vladislav Sandler, CEO & Co-founder of Hemogenyx, commented: "The issue of the European patent is significant for the Company as it extends Hemogenyx's commercial rights in Europe, thereby further solidifying and protecting Hemogenyx's position as a leader in the area of cell therapy, and helping to place Hu-PHECs at the foundation of the development of novel methods of combatting blood cancers and auto-immune diseases."